A Study to Evaluate the Tolerance and Pharmacokinetics of TQB3602 Capsule

Summary

This is a study to evaluate the tolerance, dose-limiting toxicity (DLT), phase II recommended dose (RP2D), and maximum tolerated dose (MTD) of single and multiple oral doses of TQB3474 in patients with advanced malignant tumors.

Timeline

Start

2020-05-28

Primary completion

2022-12-30

Completion

2022-12-30

Drugs

Indications